A. Robert MacLeod, Ph.D.
Senior Director, Discovery Biology
Dr. MacLeod is the Senior Director of Discovery Biology at Takeda San Diego. Dr. MacLeod's principal responsibilities include managing the research activities of the structural biology, enzyme pharmacology, cell pharmacology and in vivo pharmacology groups.
Prior to joining Takeda San Diego, Dr. MacLeod served as Executive Director of Pharmacology and Cell Biology at MethylGene Inc., where he was a founding scientist and a key contributor to the growth of its multidisciplinary drug discovery team. During his tenure at MethylGene, Dr. MacLeod was involved in therapeutic programs in oncology, inflammation and antiinfective discovery. These efforts led to the identification and clinical development of several investigational drugs including, MG98, a DNA methyltransferase inhibitor, MGCD0103, a histone deacetylse inhibitor currently in Phase II studies for oncology and MG-265 a c-Met multitargeted kinase inhibitor for oncology.
Dr. MacLeod has co-authored over 40 manuscripts and abstracts and is co-inventor on 10 United States patents. Dr. MacLeod has been a member of two US-NIH-National Cancer Institute's Core Committees and has served as a scientific reviewer for many high-impact journals. Dr. MacLeod received his Ph.D. from McGill University where he was involved with pioneering studies into the role of DNMT enzymes in oncogenic transformation and trained as a Postdoctoral fellow at Isis Pharmaceuticals, Inc. where he studied the mechanisms of novel cancer drugs.
